Lead Product(s) : Encoberminogene Rezmadenovec
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Jeito Capital
Deal Size : $67.5 million
Deal Type : Series B Financing
XyloCor Secures $67.5M Series B for Cardiovascular Gene Therapy
Details : The financing will support the company in advancing the clinical development of XC001 (encoberminogene rezmadenovec) for the treating Refractory Angina.
Product Name : XC001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 07, 2025
Lead Product(s) : Encoberminogene Rezmadenovec
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Jeito Capital
Deal Size : $67.5 million
Deal Type : Series B Financing
Lead Product(s) : Encoberminogene Rezmadenovec,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Exelixis & Merck Collaborate on Zanzalintinib + KEYTRUDA® for Head/Neck Cancer & RCC
Details : The collaboration aims to evaluate Exelixis’ TKI XL092 (zanzalintinib) with Merck’s Keytruda (pembrolizumab) for HNSCC, and with Welireg (belzutifan), an oral HIF-2 alpha inhibitor, for RCC.
Product Name : XL092
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 14, 2024
Lead Product(s) : Encoberminogene Rezmadenovec,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Casdatifan,Encoberminogene Rezmadenovec
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Hercules Capital
Deal Size : Undisclosed
Deal Type : Financing
Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital
Details : The proceeds will be used to rapidly advance AB521 (casdatifan), its potential best-in-class HIF-2a inhibitor, for the treatment of renal cell cancer.
Product Name : AB521
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 27, 2024
Lead Product(s) : Casdatifan,Encoberminogene Rezmadenovec
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Hercules Capital
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Encoberminogene Rezmadenovec
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XC001 (encoberminogene rezmadenovec) is designed to promote new blood vessels in the heart that will bypass diseased blood vessels and improve blood flow in patients with refractory angina.
Product Name : XC001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 18, 2023
Lead Product(s) : Encoberminogene Rezmadenovec
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Encoberminogene Rezmadenovec,Casdatifan
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Arcus Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The companies will enter into a clinical trial collaboration evaluating XL092 (zanzalintinib), a tyrosine kinase inhibitor, in combination with AB521 in patients with advanced solid tumors including clear cell renal cell carcinoma.
Product Name : XL092
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 12, 2023
Lead Product(s) : Encoberminogene Rezmadenovec,Casdatifan
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Arcus Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Encoberminogene Rezmadenovec,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XL092 (Zanzalintinib) is a Vegf/metaxl/mer Inhibitor small molecule drug candidate, which is currently being evaluated in combination with "Pembrolizumab" for the treatment of PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and...
Product Name : XL092
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 12, 2023
Lead Product(s) : Encoberminogene Rezmadenovec,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Encoberminogene Rezmadenovec
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XC001 is designed to promote new blood vessels in the heart that will bypass diseased blood vessels and improve blood flow. By restoring blood flow, it may decrease chest pain associated with refractory angina.
Product Name : XC001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 26, 2023
Lead Product(s) : Encoberminogene Rezmadenovec
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Encoberminogene Rezmadenovec,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zanzalintinib, which was adopted as the generic name for XL092, is a next-generation tyrosine kinase inhibitor (TKI) in development for multiple advanced tumor types. Zanzalintinib is currently being developed for the treatment of advanced solid tumors.
Product Name : XL092
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 22, 2022
Lead Product(s) : Encoberminogene Rezmadenovec,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Encoberminogene Rezmadenovec,Atezolizumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XL092 demonstrated preliminary clinical activity similar to that observed with cabozantinib in phase 1 across a range of solid tumors and dose levels, with a manageable safety profile.
Product Name : XL092
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 09, 2022
Lead Product(s) : Encoberminogene Rezmadenovec,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Encoberminogene Rezmadenovec
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XC001 (encoberminogene rezmadenovec) is a locally administered, single-dose gene therapy currently in development as a novel approach to treating patients with refractory angina who have no other medical and surgical options.
Product Name : XC001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 28, 2022
Lead Product(s) : Encoberminogene Rezmadenovec
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable